April 2009
Volume 50, Issue 13
ARVO Annual Meeting Abstract  |   April 2009
Oral Mifepristone for Chronic Central Serous Chorioretinopathy
Author Affiliations & Notes
  • J. S. Nielsen
    Ophthalmology, Northwestern University, Chicago, Illinois
    Vitreoretinal Diseases and Surgery, Wolfe Eye Clinic, West Des Moines, Iowa
  • A. Bacchawat
    Ophthalmology, Northwestern University, Chicago, Illinois
  • L. M. Jampol
    Ophthalmology, Northwestern University, Chicago, Illinois
  • Footnotes
    Commercial Relationships  J.S. Nielsen, None; A. Bacchawat, None; L.M. Jampol, None.
  • Footnotes
    Support  Macula Foundation
Investigative Ophthalmology & Visual Science April 2009, Vol.50, 764. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      J. S. Nielsen, A. Bacchawat, L. M. Jampol; Oral Mifepristone for Chronic Central Serous Chorioretinopathy. Invest. Ophthalmol. Vis. Sci. 2009;50(13):764.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: : Chronic central serous chorioretinopathy (CSC) can result in permanent loss of vision from retinal thinning and RPE atrophy. Many cases of chronic CSC do not respond to treatment. Glucocorticoids have been implicated in the pathogenesis of CSC, and blocking glucocorticoid action may be helpful its treatment. Our purpose is to see if Mifepristone (Mifeprex, RU486, Danco Laboratories), an oral glucocorticoid receptor antagonist, may be helpful in cases of chronic CSC.

Methods: : Seven patients with varying degrees of chronic CSC not amenable to treatment with thermal laser or PDT were enrolled in an IRB approved open label treatment protocol with oral mifepristone 200mg daily for 12 weeks. Visual acuity, clinical examination, angiography, and OCT were performed prior to enrollment and repeated every four weeks over the course of treatment. LFTs were obtained for all subjects at enrollment and were rechecked after 4 weeks of treatment and upon conclusion of the protocol. Pregnancy was ruled out by serum bHCG in female subjects.

Results: : All patients completed the 12 week mifepristone protocol without adverse events. No elevation of liver enzymes were found in any patients over the course of treatment. Two patients demonstrated a clinical response to oral mifepristone. One patient had vision improve from 20/80 to 20/50 with complete resolution of subretinal fluid and retinal edema. Another patient had vision improve from CF3FT to 20/200 with a significant reduction in retinal edema.

Conclusions: : Daily oral mifepristone does have a beneficial effect in treating some cases of chronic CSC. Further study is warranted.

Keywords: retina 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.